Trial Profile

Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Malignant thymoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

21 Sep 2020 Status changed to active, no longer recruiting as per results presented at the 45th European Society for Medical Oncology Congress
21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
31 May 2020 Results (n=22) assessing safety and efficacy of TQ-B2450 plus anlotinib in advanced solid tumors, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com